On ECHEMI
Home > Drugs > Jinhua Enterprise (Group) Co., Ltd. Xi'an Jinhua Pharmaceutical Factory
Jinhua Enterprise (Group) Co., Ltd. Xi'an Jinhua Pharmaceutical Factory
  • Founded in:

    1997-11-05
  • Country:

    China China
  • Address:

    No. 202, Keji 4th Road, High-tech Industrial Development Zone, Xi'an High-tech Zone
  • Tax NO.:

    9161000092056049XF
  • Registered Funds:

    -
  • Website:

  • Email:

Related Drugs
Inosine oral solution
Chemical name: 9β-D-ribosyl hypoxanthine Molecular weight: C10H12N4O5
Name Description Content CAS NO. Registered Holders
Inosine

It participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

More

It participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

58-63-9 8
Inosine oral solution
Chemical name: 9β-D-ribosyl hypoxanthine Molecular weight: C10H12N4O5
Name Description Content CAS NO. Registered Holders
Inosine

It participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

More

It participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

58-63-9 8
Inosine oral solution
Chemical name: 9β-D-ribosyl hypoxanthine Molecular weight: C10H12N4O5
Name Description Content CAS NO. Registered Holders
Inosine

It participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

More

It participates in cellular energy metabolism and protein synthesis in the body, increases the activity of related metabolic enzymes, improves liver function, and promotes the recovery of damaged liver.

58-63-9 8
Vitamin C Hesperidin Granules
Each bag of this product contains 100 mg of vitamin C and 60 mg of hesperidin methyl.
Name Description Content CAS NO. Registered Holders
Ascorbic Acid

Participate in the body's antibody, collagen formation and tissue repair, as well as the metabolism of carbohydrates, fats and proteins, and maintain blood vessel integrity

More

Participate in the body's antibody, collagen formation and tissue repair, as well as the metabolism of carbohydrates, fats and proteins, and maintain blood vessel integrity

100mg 50-81-7 28
Hesperidin

Maintains normal vascular permeability and prevents capillary bleeding

More

Maintains normal vascular permeability and prevents capillary bleeding

60mg 0
Clarithromycin Capsules
Clarithromycin
Name Description Content CAS NO. Registered Holders
Clarithromycin

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

More

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

81103-11-9 46
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.